Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly and Novo Nordisk currently dominate the market for the new class of GLP-1 receptor agonist medications, which work by mimicking the effect of a gut hormone that reduces appetite.

Eli Lilly announced that it is expanding its offerings of its hit weight loss drug Zepbound on Tuesday, a few days after the Food and Drug Administration lifted a shortage on Novo Nordisk’s Wegovy and ...

Eli Lilly is one of the top growth stocks in the pharmaceutical industry. Vertex Pharmaceuticals boasts multiple growth avenues. Amgen could tap into more growth opportunities by entering the GLP ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE ...